Supportive care

Advances in supportive care for multiple myeloma.Raje NS et al. J Natl Compr Canc Netw. 2014 Apr 1;12(4):502-11.Surgical management of primary tumors of the cervical spine: surgical considerations and avoidance of complications.Kaloostian PE et al. Neurol Res. 2014 Apr 10:1743132814Y0000000367. [Epub ahead of print].Post-operative Cement Augmentation after 360-degree Fusion for Highly Unstable Vertebral Fractures in…

Current treatments

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.Mateos MV et al. Haematologica. 2014 Apr 24. [Epub ahead of print].Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.Ahn SY et…

Diagnostic tests and prognostic indicators

CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study. Petitprez V et al. Int J Lab Hematol. 2014 Mar 24. doi: 10.1111/ijlh.12216. [Epub ahead of print]. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Martinez-Lopez…

Biology and genetics

Autophagy in Plasma Cell Pathophysiology. Oliva L et al. Front Immunol. 2014 Mar 12;5:103. eCollection 2014. Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Olsen OE et al. Blood Cancer J. 2014 Mar 21;4:e196. doi: 10.1038/bcj.2014.16. Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++…

General

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation. A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma and the European Myeloma Network. Ozaki S et al. Acta Haematol. 2014 Mar 22;132(2):211-219. [Epub ahead of print]. Pathways for blood and bowel cancer patients…

Emerging treatments

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Korde N et al. Haematologica. 2014 Mar 21. [Epub ahead of print]. Sotatercept in patients with osteolytic lesions of multiple myeloma. Abdulkadyrov KM et al. Br J Haematol. 2014 Mar 21. doi: 10.1111/bjh.12835. [Epub ahead of print]. Evolution of carfilzomib dose and…

Supportive care

Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK et al. Biol Blood Marrow Transplant. 2014 Mar 6. pii: S1083-8791(14)00148-7. doi: 10.1016/j.bbmt.2014.02.025. [Epub ahead of print].

Plasma Exchange for Kidney Disease: What Is the Best Evidence?
Hildebrand AM et al. Adv Chronic Kidney Dis. 2014 Mar;21(2):217-227. doi: 10.1053/j.ackd.2014.01.008.

Current treatments

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.Fouquet G et al. J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.Mark TM et al. Leuk Lymphoma. 2014 Mar 25. [Epub ahead of…